HER2

News

AZ, Daiichi challenge Roche with EU okay for earlier use of ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.

News

Byondis cues up US, EU decisions on breast cancer ADC in 202...

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight com

Oncology

Redefining the approach to cancer care – a mission to improv...

Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million deaths, making cancer the

News

Enhertu gets breakthrough tag in HER2-low breast cancer

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

News

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potenti

AZ, Daiichi challenge Roche with EU okay for earlier use of ...

Byondis cues up US, EU decisions on breast cancer ADC in 202...

Redefining the approach to cancer care – a mission to improv...

Enhertu gets breakthrough tag in HER2-low breast cancer

FDA starts speedy review of Enhertu in lung cancer

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

HER2

Editor's Picks